鼻内催产素治疗苯二氮卓戒断的效果:一项试点随机对照试验
Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot Randomized Parallel Group Placebo-Controlled Trial
The goal of this clinical trial is to learn if oxytocin administered as a nasal spray will reduce withdrawal symptoms in adults during benzodiazepine tapering for 21 days. It will also learn about the safety of oxytocin. The main questions it aims to answer are:
Does oxytocin reduce benzodiazepine withdrawal symptoms and make it easier to succeed tapering? Does oxytocin help reduce sleep difficulties and anxiety or restlessness during benzodiazepine tapering? Does oxytocin help reduce benzodiazepine craving?
We will compare oxytocin nasal spray to a placebo nasal spray containing regular saline to see if oxytocin works accordingly.
Participants will:
Take oxytocin or a placebo nasal spray, three times daily for 21 days during inpatient benzodiazepine tapering.
Fill out an online questionnaire every day and keep a record of their symptoms.
研究概览
详细说明
Background Benzodiazepine withdrawal can be challenging, often accompanied by severe anxiety, insomnia, and other withdrawal symptoms. Recent studies suggest that intranasal oxytocin (OT) may have anxiolytic properties and could potentially ease withdrawal symptoms. This study aims to evaluate the efficacy and safety of intranasal OT in the treatment of benzodiazepine withdrawal.
Objectives The primary objective is to evaluate if intranasal OT can reduce withdrawal symptoms in patients during benzodiazepine tapering. Secondary objectives include evaluating the safety and tolerability of intranasal OT and its impact on anxiety levels and sleep quality.
Methods
- Design: This is a randomized, parallel-group, placebo-controlled trial.
- Participants: Adults (aged 18-65) undergoing inpatient benzodiazepine tapering.
- Intervention: Participants were randomly assigned to receive either intranasal OT (16 IU per administration, given three times daily, for a total daily dose of 48 IU) or placebo for 21 days during inpatient benzodiazepine tapering.
- Assessments: Withdrawal symptoms were measured using the Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) scale. Anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), and sleep was measured using the Insomnia Severity Index (ISI), actigraphy, and Somnofy.
Procedure
- Screening: Eligible participants underwent a screening process, including medical history, physical examination, and baseline assessments.
- Randomization: Participants were randomly assigned to the OT or placebo group.
- Treatment Phase: Participants self-administered the nasal spray three times daily for three weeks. Participants filled out daily questionnaires to monitor symptoms and side effects. Urine samples for toxicology were collected twice weekly during the intervention period, and blood samples were collected at screening and at the end of the intervention period.
- Post-Treatment Follow-Up: Participants were assessed at the end of the treatment period and again four and twelve weeks post-treatment to evaluate the persistence of effects.
Expected Outcomes It was hypothesized that participants receiving intranasal OT would experience a significant reduction in withdrawal symptoms compared to the placebo group. Improvements in anxiety levels and sleep quality were also anticipated.
Significance This study could provide preliminary evidence for the use of intranasal OT as a supportive treatment for benzodiazepine withdrawal, potentially improving patient outcomes and comfort during the tapering process.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Trøndelag
-
Trondheim、Trøndelag、挪威、7091
- Blue Cross, Clinic Lade
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients aged 18 - 65 years, taking benzodiazepines at a daily dose of 20-80 mg diazepam-equivalent, and requiring inpatient benzodiazepine withdrawal. Included patients must consent to participate in the study.
Exclusion Criteria:
- Female patients will be excluded if they are pregnant or are planning to become so, or if they are breast-feeding. Individuals incapable of completing questionnaires or giving informed consent will be excluded. Patients with concurrent acute medical or psychiatric illness requiring acute care hospitalization, misuse or dependency of alcohol or pregabalin/gabapentin will be excluded.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Participants in the placebo arm will receive a saline solution. Saline is an inert substance, meaning it has no therapeutic effect, making it an ideal placebo. The saline solution will be administered in the same manner as the experimental treatment. The treatment is administered intranasally. The treatment is blinded. Neither the participants nor the researchers know who is receiving the placebo and who is receiving the active treatment. Participants in the placebo arm will be monitored the same as those in the treatment arm. Participants will be fully informed about the possibility of receiving a placebo and will provide informed consent. The same outcome measures will be used for both the placebo and treatment arms. |
Saline intranasal placebo comparator |
|
实验性的:Oxytocin
Participants in this arm will receive intranasal oxytocin. The dosage and administration schedule will be consistent with the study protocol. Participants will receive 48 international units (IU) of oxytocin. The oxytocin will be administered intranasally using a nasal spray. Participants will insert the nasal spray container approximately 1 cm into each nostril and spray. They will wait 15 seconds before repeating administration until they have received a total of 4 puffs (2 in each nostril) per session thrice daily. |
Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Benzodiazepine withdrawal symptoms
大体时间:21 days
|
Benzodiazepine withdrawal symptoms severity is measured with CIWA-B score, a 20-item scale where each item can be assigned a score from 0 to 4, i.e. the total score can range from 0 and 80 points. CIWA-B score will be measured daily from baseline (i.e. the day before the intervention starts) to day 21. |
21 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Benzodiazepine craving
大体时间:21 days
|
To test whether there is a difference between oxytocin and placebo on craving. Craving is measured daily with a Norwegian translation of the Brief Substance Craving Scale, adapted to benzodiazepines. Three items covering the intensity, frequency, and duration of craving during the past 24 hours are each scored from 0 to 4, giving a total score from 0 to 12. Higher scores indicate stronger craving, that is, a worse outcome. A fourth item records the number of craving episodes during the past 24 hours and is reported separately. The change in scores from baseline to day 21 is compared between the two study groups. |
21 days
|
|
Benzodiazepine anxiety and depression symptoms
大体时间:21 days
|
To test whether there is a difference between oxytocin and placebo on rebound anxiety and depression symptoms. Symptoms are measured with the Hospital Anxiety and Depression Scale (HADS), a 14-item scale where each item is scored from 0 to 3, giving subscale scores from 0 to 21 for anxiety and for depression and a total score from 0 to 42. Higher scores indicate more severe symptoms, that is, a worse outcome. HADS is measured weekly from baseline to day 21, and the change in scores from baseline to day 21 is compared between the two groups. |
21 days
|
|
Benzodiazepine sleep distress
大体时间:21 days
|
To test whether there is a difference between oxytocin and placebo on sleep. Sleep difficulties are measured with the Insomnia Severity Index (ISI), a 7-item scale where each item is scored from 0 to 4, giving a total score from 0 to 28. Higher scores indicate more severe insomnia, that is, a worse outcome. Sleep variables are also assessed by actigraphy and Somnofy. Scores are compared between the two study groups from baseline to day 21 during the intervention. |
21 days
|
|
Benzodiazepine tapering "freezes"
大体时间:21 days
|
To test whether there is a difference between oxytocin and placebo in the number of "freezes" in diazepam tapering. A "freeze" (not reducing the diazepam dose as scheduled during tapering) will be noted for each subject and compared between the two study groups. |
21 days
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Follow-up: Relapse
大体时间:15 weeks
|
To test whether there is a difference between oxytocin and placebo in time to first benzodiazepine intake (up to 12 weeks after discharge). Comparing time (number of days) to first self-reported benzodiazepine intake after discharge (week 3) between the two study groups, by registration on the follow-up visits at week 7 and week 15. |
15 weeks
|
|
Follow-up: Benzodiazepine withdrawal symptoms
大体时间:15 weeks
|
Difference between the oxytocin and placebo group in withdrawal symptoms measured with the Clinical Institute Withdrawal Assessment Scale for Benzodiazepines (CIWA-B) at week 7 and week 15 after discharge. CIWA-B is a 20-item scale where each item is scored from 0 to 4, giving a total score from 0 to 80. Higher scores indicate more severe withdrawal symptoms, that is, a worse outcome. |
15 weeks
|
|
Follow-up: Benzodiazepine craving
大体时间:15 weeks
|
To test whether there is a difference between oxytocin and placebo on craving at week 7 and week 15 after discharge. Craving is measured with a Norwegian translation of the Brief Substance Craving Scale, adapted to benzodiazepines. Three items covering the intensity, frequency, and duration of craving during the past 24 hours are each scored from 0 to 4, giving a total score from 0 to 12. Higher scores indicate stronger craving, that is, a worse outcome. A fourth item records the number of craving episodes during the past 24 hours and is reported separately. Scores are compared between the two study groups. |
15 weeks
|
|
Follow-up: Benzodiazepine anxiety and depression symptoms
大体时间:15 weeks
|
To test whether there is a difference between oxytocin and placebo on rebound anxiety and depression symptoms at week 7 and week 15 after discharge. Symptoms are measured with the Hospital Anxiety and Depression Scale (HADS), a 14-item scale where each item is scored from 0 to 3, giving subscale scores from 0 to 21 for anxiety and for depression and a total score from 0 to 42. Higher scores indicate more severe symptoms, that is, a worse outcome. Scores are compared between the two study groups. |
15 weeks
|
|
Follow-up: Benzodiazepine sleep distress
大体时间:15 weeks
|
To test whether there is a difference between oxytocin and placebo on sleep distress at week 7 and week 15 after discharge. Sleep difficulties are measured with the Insomnia Severity Index (ISI), a 7-item scale where each item is scored from 0 to 4, giving a total score from 0 to 28. Higher scores indicate more severe insomnia, that is, a worse outcome. Scores are compared between the two study groups. |
15 weeks
|
合作者和调查者
调查人员
- 学习椅:Tone Aurora Pleym, MD, PhD-candidate、NTNU, Blue Cross, Clinic Lade, St. Olavs hospital
- 首席研究员:Olav Spigset, MD, PhD、Department of Clinical Pharmacology, St. Olavs Hospital, and Norwegian University of Science and Technology (NTNU)
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.